Chronic urotensin II infusion enhances macrophage foam cell formation and atherosclerosis in apolipoprotein E-knockout mice

Journal of Hypertension

Volumn 26, Issue 10, 2008, Pages 1955-1965

  Shiraishi, Yuji ^a   Watanabe, Takuya ^b   Suguro, Toshiaki ^a   Nagashima, Masaharu ^a   Kato, Rina ^b   Hongo, Shigeki ^b   Itabe, Hiroyuki ^b   Miyazaki, Akira ^b   Hirano, Tsutomu ^a   Adachi, Mitsuru ^a  

^a First Dept of Internal Medicine   (Japan)

^b SHOWA UNIVERSITY   (Japan)

Author keywords

atherosclerosis; foam cell formation; macrophage; oxidized low density lipoprotein; reactive oxygen species; urotensin II

Indexed keywords

4 AMINOQUINOLINE; APOLIPOPROTEIN E; CD36 ANTIGEN; CHOLESTEROL ACYLTRANSFERASE; OXIDIZED LOW DENSITY LIPOPROTEIN; REACTIVE OXYGEN METABOLITE; UROTENSIN II; LOW DENSITY LIPOPROTEIN; SCAVENGER RECEPTOR A; STEROL O ACYLTRANSFERASE 1; STEROL O-ACYLTRANSFERASE 1; UNCLASSIFIED DRUG; UROTENSIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; MACROPHAGE; MALE; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING; ANIMAL; ATHEROGENIC DIET; FOAM CELL; GENETICS; METABOLISM; MOUSE; MOUSE MUTANT; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ANTIGENS, CD36; APOLIPOPROTEINS E; ATHEROSCLEROSIS; DIET, ATHEROGENIC; FOAM CELLS; LIPOPROTEINS, LDL; MALE; MICE; MICE, KNOCKOUT; REACTIVE OXYGEN SPECIES; SCAVENGER RECEPTORS, CLASS A; STEROL O-ACYLTRANSFERASE; UROTENSINS;

EID: 58149127425     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32830b61d8     Document Type: Article

References (60)

1. Ames RS, Sarau HM, Cambers JK, Willette RN, Aiyar NV, Romanic AM, et al. Human urotensin II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999; 401:282-286.
2. Douglas SA, Ohlstein EH. Human urotensin-II, the most potent mammalian vasoconstrictor identi?ed to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc Med 2000;10:229-237.
3. Maguire JJ, Kuc RE, Kleinz MJ, Davenport AP. Immunocytochemical localization of the urotensin-II receptor, UT, to rat and human tissues: relevance to function. Peptides 2008; 29:735-742.
4. Charles CJ, Rademaker MT, Richards AM, Yandle TG. Urotensin II: evidence for cardiac, hepatic and renal production. Peptides 2005; 26:2211-2214.
5. Cheung BM, Leung R, Man YB, Wong LY. Plasma concentration of urotensin II is raised in hypertension. J Hypertens 2004; 22:1341-1344.
6. Suguro T,Watanabe T, Ban Y, Kodate S,Misaki A, Hirano T, et al. Increased human urotensin II levels are correlated with carotid atherosclerosis in essential hypertension. Am J Hypertens 2007; 20:211-217.
7. Heringlake M, Kox T, Uzun O, Will B, Bahlmann L, Klaus S, et al. The relationship between urotensin II plasma immunoreactivity and left ventricular ?lling pressures in coronary artery disease. Regul Pept 2004; 121:129-136.
8. Ng LL, Loke I, O'Brien RJ, Squire IB, Davies JE. Plasma urotensin in human systolic heart failure. Circulation 2002; 106:2877-2880.
9. Suguro T, Watanabe T, Kodate S, Xu G, Hirano T, Adachi M, Miyazaki A. Increased plasma urotensin-II levels are associated with diabetic retinopathy and carotid atherosclerosis in type 2 diabetes mellitus. Clin Sci (Lond) 2008 (in press).
10. Totsune K, Takahashi K, Arihara Z, Sone M, Satoh F, Ito S, et al. Role of urotensin II in patients on dialysis. Lancet 2001; 358:810-811.
11. Watanabe T, Kanome T, Miyazaki A, Katagiri T. Human urotensin II linking hypertension and coronary artery disease. Hypertens Res 2006; 29:375-387.
12. Maguire JJ, Kuc RE, Wiley KE, Kleinz MJ, Davenport AP. Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries. Peptides 2004; 25:1767-1774.
13. Bousette N, Patel L, Douglas SA, Ohlstein EH, Giaid A. Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis 2004; 176:117-123.
14. HassanGS, Douglas SA,Ohlstein EH,Giaid A. Expression of urotensin-II in human coronary atherosclerosis. Peptides 2005; 26:2464-2472.
15. Djordjevic T, BelAiba RS, Bonello S, Pfeilschifter J, Hess J, Gorlach A. Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arterioscler Thromb Vasc Biol 2005; 25:519-525.
16. Shi L, Ding W, Li D, Wang Z, Jiang H, Zhang J, Tang C. Proliferation and antiapoptotic effects of human urotensin II on human endothelial cells. Atherosclerosis 2006; 188:260-264.
17. Tzanidis A, Hannan RD, Thomas WG, Onan D, Autelitano DJ, See F, et al. Direct actions of urotensin II on the heart: implications for cardiac ?brosis and hypertrophy. Circ Res 2003; 93:246-253.
18. Watanabe T, Suguro T, Kanome T, Sakamoto Y, Kodate S, Hagiwara T, et al. Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages. Hypertension 2005; 46:738-744.
19. Watanabe T, Pakala R, Katagiri T, Benedict CR. Synergistic effect of urotensin II with serotonin on vascular smooth muscle cell proliferation. J Hypertens 2001; 19:2191-2196.
20. Watanabe T, Pakala R, Katagiri T, Benedict CR. Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation 2001; 104:16-18.
21. Miyazaki A, Sakashita N, Lee O, Takahashi K, Horiuchi S, Hakamata H, et al. xpression of ACAT-1 protein in human atherosclerotic lesions and cultured human monocytes-macrophages. Arterioscler Thromb Vasc Biol 1998; 18:1568-1574.
22. Weiss D, Kools JJ, Taylor WR. Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-de?cient mice. Circulation 2001; 103:448-454.
23. Hirano T, Ran J, Adachi M. Opposing actions of angiotensin II type 1 and 2 receptors on plasma cholesterol levels in rats. J Hypertens 2006; 24:103-108.
24. Ran J, Hirano T, Adachi M. Angiotensin II infusion increases hepatic triglyceride production via its type 2 receptor in rats. J Hypertens 2005; 23:1525-1530.
25. Itabe H, Yamamoto H, Imanaka T, Shimamura K, Uchiyama H, Kimura J, et al. Sensitive detection of oxidatively modi?ed low density lipoprotein using a monoclonal antibody. J Lipid Res 1996; 37:45-53.
26. Hayashi T, Morishita Y, Hayashi I, Masuda M, Fujita K, Kusunoki Y, et al. Rapid and multisample determination of reactive oxygen species in human sera. JJCLA 2005; 30:216-20.
27. Fukuhara-Takaki K, SakaiM, Sakamoto Y, TakeyaM, Horiuchi S. Expression of class A scavenger receptor is enhanced by high glucose in vitro and under diabetic conditions in vivo. J Biol Chem 2005; 280:3355-3364.
28. Suzuki J, Iwai M, Li Z, Li JM, Min LJ, Ide A, et al. Effect of combination of calcium ntagonist, azelinidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-de?cient mice. J Hypertens 2005; 23:1383-1389.
29. Holvoet P,Macy E, LandeloosM, Jones D, Nancy JS, deWerf FV, Russell P. Analytical performance and diagnostic accuracy of immunometric assays for the measurement of circulating oxidized LDL. Clin Chem 2006; 52:760-764.
30. Hongfang J, Bailin C, Bin Z, Chunyu Z, Xinmin L, Weijin Z, et al. Effects of hydrogen sul?de on hypoxic pulmonary vascular structural remodeling. Life Sci 2006; 78:1299-1309.
31. Douglas SA, Tayara L, Ohlstein EH, Halawa N, Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet 2002; 359:1990-1997.
32. Johns DG, Ao Z, Naselsky D, Herold CL, Maniscalco K, Sarov-Blat L, et al. Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of in?ammatory mediators. Naunyn Schmiedebergs Arch Pharmacol 2004; 370:238-250.
33. Birker-Robaczewska M, Boukhadra C, Studer R, Mueller C, Binkert C,Nayler O. The xpression of urotensin II receptor (U2R) is up-regulated by interferon-g. J Recept Signal Transduct Res 2003; 23:289-305.
34. Segain JP, Rolli-Derkinderen M, Gervois N, Raingeard de la Ble tie re D, Loirand G, Pacaud P. Urotensin II is a new chemotactic factor for UT receptor-expressing monocytes. J Immunol 2007; 179:901-909.
35. Wang ZJ, Shi LB, Xiong ZW, Zhang LF, Meng L, Bu DF, et al. Alteration of vascular urotensin II receptor in mice with apolipoprotein E gene knockout. Peptides 2006; 27:858-863.
36. Peng X, Yin H,Wang LH,Chai SB, Shu JL, TangCS. Effects of oxidized-low density lipoprotein on expression of urotensin II receptor GPR14 in rat aortic smooth muscle cells. Sheng Li Xue Bao 2000; 52:455-458.
37. Rakowski E, Hassan GS, Dhanak D, Ohlstein EH, Douglas SA, Giaid A. A role for urotensin II in restenosis following balloon angioplasty: use of a selective UT receptor blocker. J Mol Cell Cardiol 2005; 39:785-791.
38. Behm DJ, Doe CP, Douglas GJ, Maniscalco K, Stankus GP, Wibberley A, et al. Urotensin-II: a novel systemic hypertensive factor in the cat. Naunyn Schmiedebergs Arch Pharmacol 2004; 369:274-280.
39. SongW, Ashton N, Balment RJ. A radioimmunoassay to detect urotensin II in the plasma of rat models of hypertension. J Physiol 2002; 544:S024.
40. Lin Y, Tsuchihashi T, Matsumura K, Fukuhara M, Ohya Y, Fujii K, Iida M. Central cardiovascular action of urotensin II in spontaneously hypertensive rats. Hypertens Res 2003; 26:839-845.
41. Gendron G, Gobeil F Jr, Belanger S, Gagnon S, Regoli D, D'Orleans-Juste P. Urotensin II-induced hypotension responses inWistar-Kyoto (Wky) and spontaneously hypertensive (Shr) rats. Peptides 2005; 26:1468-1474.
42. Watson AMD, Lambert GW, Smith KJ, May CN. Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions. Hypertension 2003; 42:373-379.
43. Gardiner SM, March JE, Kemp PA, Maguire JJ, Kuc RE, Davenport AP, Bennett T. Regional heterogeneity in the haemodynamic responses to urotensin II infusion in relation to UT receptor localization. Br J Pharmacol 2006; 147:612-621.
44. Harris GS, Lust RM, Katwa L. Hemodynamic effects of chronic urotensin II administration in animals with and without aorto-caval ?stula. Peptides 2007; 28:1483-1489.
45. Harris GS, Lust RM, Katwa L. Hemodynamic effects of chronic urotensin II administration in animals with and without aorto-caval ?stula. Peptides 2007; 28:1483-1489.
46. Kompa AR, Thomas WG, See F, Tzanidis A, Hannan RD, Krum H. Cardiovascular role of urotensin II: effect of chronic infusion in the rat. Peptides 2004; 25:1783-1788.
47. Sung HJ, Eskin SG, Sakurai Y, Yee A, Kataika N, McIntire LV. Oxidative stress produced with cell migration increases synthetic phenotype of vascular smooth muscle cells. Ann Biomed Eng 2005; 33:1546-1554.
48. Sauzeau V, Mellionnec EL, Bertoglio J, Scalbert E, Pacaud P, Loirand G. Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ Res 2001; 88:1102-1104.
49. Watanabe T, Takahashi K, Kanome T, Hongo S, Koba S, Katagiri T, et al. Human urotensin-II potentiates mildly oxidized LDL-induced vascular smooth muscle cell proliferation: comparison with other vasoactive agents and hydrogen peroxide. Hypertens Res 2006; 29:821-831.
50. Dai HY, Ge ZM, Li YH. Effect of urotensin II on proliferative potential and phosphorylation of extracellular signal-regulated kinase 1/2 of adventitial ?broblasts from spontaneously hypertensive rat. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2006; 28:776-780.
51. Wang H, Mehta JL, Chen K, Zhang X, Li D. Human urotensin II modulates collagen synthesis and the expression ofMMP-1 in human endothelial cells. J Cardiovasc Pharmacol 2004; 44:577-581.
52. Cirillo P,De Rosa S, PacileoM,Garqiulo A, Angri V, Fiorentino I, et al.Human urotensin II induces tissue factor and cellular adhesionmolecules expression in human coronary endothelial cells: an emerging role for urotensin II in cardiovascular disease. J Thromb Haemost 2008; 6:726-736.
53. Takemura T, Sakai M, Matsuda H, Matsumura T, Biwa T, Anami Y, et al. Effects of probucol on cholesterol metabolism in mouse peritoneal macrophages: inhibition of HDL-mediated cholesterol ef?ux. Atherosclerosis 2000; 152:347-357.
54. De Kimpe SJ, Anggard EE, Carrier MJ. Reactive oxygen species regulatemacrophage scavenger receptor type I, but not type II, in the human monocytic cell line THP-1. Mol Pharmacol 1998; 53:1076-1082.
55. Svensson L, Noren K, Wiklund O, Lindmark H, Ohlsson B, Hulten LM. Inhibitory effects of N-acetylcysteine on scavenger receptor class A expression in human macrophages. J Intern Med 2002; 251:437-446.
56. Dhanak D, Neeb MJ, Douglas SA. Urotensin-II receptor modulators. Annu Rep Med Chem 2003; 38:99-110.
57. Lescot E, Bureau R, Rault S. Nonpeptide urotensin-II receptor agonists and antagonists: review and structure-activity relationships. Peptides 2008; 29:680-690.
58. Tarui N, Santo T, Mori M, Watanabe H. Takeda Chemical Industries (assignee). Quinoline derivatives as vasoactive agents exhibiting orphan receptor GPR14 protein antagonism. PCT Int Appl.; 2001 (WO2001066143).
59. Sidharta PN, Wagner FD, Bohnemeier H, Jungnik A, Halabi A, Krahenbuhl S, et al. Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in microalbuminuric, diabetic patients. Clin Pharmacol Ther 2006; 80:246-256.
60. Ong KL, Wong LY, Cheung BM. The role of urotensin II in the metabolic syndrome. Peptides 2008; 29:859-867.